Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Research & Development (2016 - 2025)

Mimedx (MDXG) has disclosed Research & Development for 15 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 33.32% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.1 million through Dec 2025, up 22.31% year-over-year, with the annual reading at $15.1 million for FY2025, 22.33% up from the prior year.
  • Research & Development hit $4.8 million in Q4 2025 for Mimedx, up from $3.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $6.0 million in Q1 2022 to a low of -$4.7 million in Q4 2022.
  • Historically, Research & Development has averaged $3.1 million across 5 years, with a median of $3.5 million in 2023.
  • Biggest five-year swings in Research & Development: tumbled 182.64% in 2021 and later soared 151.46% in 2023.
  • Year by year, Research & Development stood at -$2.8 million in 2021, then crashed by 66.6% to -$4.7 million in 2022, then skyrocketed by 151.46% to $2.4 million in 2023, then surged by 46.77% to $3.6 million in 2024, then skyrocketed by 33.32% to $4.8 million in 2025.
  • Business Quant data shows Research & Development for MDXG at $4.8 million in Q4 2025, $3.7 million in Q3 2025, and $3.3 million in Q2 2025.